Paris, 14 February 2013 – NYSE Euronext (NYX) today announced the listing on NYSE Alternext in Paris of Spineway, a company specialised in surgical implants and instruments used to treat spinal column pathologies.
Spineway lists on NYSE Alternext
Founded in 2005, Spineway designs, manufactures and markets leading-edge surgical instruments and implants that make spinal surgery more effective. Based in the Lyon suburb of Bron, the company has a distribution network of 48 specialists serving markets outside France. With nearly 30 employees, Spineway has harnessed its founders’ 15 years of experience to build a worldwide reputation for expertise and technical excellence in its field.
Spineway (ticker: ALSPW) was listed through admission to trading of 2,800,500 existing shares and 595,003 new shares issued as a private placement with qualified investors. The private placement raised a total of €4.9 million.
The admission and issue price of Spineway was set at €7.47 per share. Market capitalisation stood at around €25.4 million on the day of listing.
“We are delighted to welcome Spineway to NYSE Alternext, our organized market dedicated to small and mid-size companies - a market with regulations matched to the needs of medtech companies,” said Marc Lefèvre, Head of European Business Development and Client Coverage, Listings Europe, at NYSE Euronext. “Spineway has won worldwide recognition as an expert in spinal column surgery. Today it is raising the capital it needs to grow by listing, which will boost its profile and appeal for investors.”
Spineway Chairman and CEO Stéphane Le Roux added, “We are very happy with Spineway’s stockmarket listing and the success of this first transaction. This important step that will enable us to step up the pace of growth significantly while maintaining the independence we have always with Philippe Laurito - ever since Spineway was founded. We want to thank all of the investors who have taken part for their interest and their trust.”
In seven years, €2.7 billion has been raised on NYSE Alternext, half through secondary issues, by companies from countries including Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US. Their market capitalisation totals over €6 billion. Today 180 companies are listed on NYSE Alternext.
Caroline Tourrier: +33 (0)1 49 27 10 82
Aelium Finance et Communication
Solène Kennis: +33 (0)1 75 77 54 68
About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets – the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca – represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: www.nyx.com.
None of the information contained in this press release constitutes an offer, solicitation or recommendation to acquire or dispose of any security or investment or to engage in any other transaction or to provide legal, tax, accounting or investment advice or services regarding the suitability or profitability of any security or investment. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by NYSE Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. NYSE Euronext offers no view on whether investments are appropriate for you and recommends you obtain independent advice in respect of such investments. Persons wishing to trade products available on NYSE Euronext markets or wishing to offer such products to third parties (whether by way of admission to listing and/or trading of products, or otherwise) are advised, before doing so, to check their legal and regulatory position in the relevant territory and to understand the related risks. NYSE Euronext does not make any recommendations regarding the merit of any company, security or other financial product or investment identified in this press release. Similarly, NYSE Euronext does not make any recommendation regarding the purchase or sale of any company, security, financial product or investment, endorsed or sponsored by any company identified in this press release. This press release is not intended to be, and shall not constitute in any way a binding or legal agreement, or impose any legal obligation or duty on NYSE Euronext or any of its affiliates. This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein.
NYSE Euronext refers to NYSE Euronext and its affiliates and references to NYSE Euronext in this publication include each and any such company as the context dictates. NYSE Euronext, New York Stock Exchange, NYSE MKT, NYSE Alternext, NYSE Arca and NYSE Liffe are registered marks of NYSE Euronext. © 2013, NYSE Euronext – All rights reserved.
Spineway specialises in the design, manufacture and marketing of surgical implants and instruments used in spinal column surgery. Its products include screw-, hook- and rod-based systems, cervical and lumbar cages, cervical systems, bone substitutes used in grafting and more. For more information, visit: www.spineway.com.